Montero-Melendez Trinidad, Perretti Mauro
The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Drug Discov Today. 2014 Jul;19(7):820-3. doi: 10.1016/j.drudis.2013.11.022. Epub 2013 Dec 6.
There is a paucity of molecules that progress through the drug development pipeline, making the drug discovery process expensive and frustrating. Innovative approaches to drug development are therefore required to maximise opportunities. Strategies such as the Connectivity Map (CMap), which compares >7000 gene expression signatures generated from more than 1000 drugs, can produce associations between currently unrelated therapeutics, unveiling new mechanisms of action and favouring drug repositioning. Here, we discuss these opportunities that could aid the drug development process and propose rigorous publication of 'omics data with open access and data sharing. We, pharmacologists of the third millennium, must aim towards maximising knowledge in an unbiased and cost-effective manner, to deliver new drugs for the global benefit of patients.
能够通过药物研发流程的分子数量稀少，这使得药物发现过程既昂贵又令人沮丧。因此，需要创新的药物研发方法来最大化机会。诸如连通性图谱（CMap）之类的策略，它比较了由1000多种药物产生的7000多个基因表达特征，可以在当前不相关的治疗方法之间产生关联，揭示新的作用机制并有利于药物重新定位。在此，我们讨论这些有助于药物研发过程的机会，并提议严格发表具有开放获取和数据共享的“组学”数据。我们，21世纪的药理学家，必须致力于以无偏见且具有成本效益的方式最大化知识，以便为全球患者提供新药。
